Cell and gene therapy (CGT) offers new hope for patients. There are essential differences between the patient, product, and system journeys for CGT vs. conventional medicines. These unique challenges present across the drug development continuum – from early stage development programs to approval and launch activities, to long term care and treatment, to strategies that support access to these potentially transformative treatments. How does industry engage patient communities in mutually beneficial ways to ensure success of CGT? What roles do industry, patients, patient organizations each play to address needs? Key topics will delineate how patient engagement in CGT is different in: educational needs, clinical trial participation, standard practices in expanded access, perspectives on pricing and the role of the patient community in these discussions, complex care needs before, during, and after administration of the therapy.